EyePoint Pharmaceuticals

42 articles with EyePoint Pharmaceuticals

• EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues

  1/11/2021

  - IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimated to be $6.2 - $6.6 million versus $7.9 million in 2019 and $20.3 - $20.7 million for the full year 2020 as compared to $16.8 million for the full year 2019 -

• EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics

  1/4/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong, has made a $15.7 million equity investment in EyePoint.

• EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split

  12/8/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m. Eastern Time today. Beginning with the opening of trading on December 9, 2020, EyePoint's common stock will trade on the Nasdaq Global Market on a split-adjusted basis under a new CUSIP number 30233G209.

• EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration

  12/3/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® technology for wet age-related macular degeneration (wet AMD).

• EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4

  11/19/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company’s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will

• EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

  11/16/2020

  Study of DEXYCU vs. Prednisolone eye drops shows high patient preference for DEXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes in DEXYCU group

• EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

  11/10/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for presentation at the upcoming American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting, taking place November 13-15, 2020. Details for the AAO presentations are as follows: Paper Presentation

• EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments

  11/5/2020

  - Total revenues of $ 15.7 million and net product revenues of $ 5. 8 million - - S equential quarterly increase in underlying customer demand of over 12 0 % for DEXYCU ® and over 5% for YUTIQ® - - EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration, remains on track for Q4 IND filing -

• EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information

  10/29/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020.

• EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants

  10/8/2020

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced an amendment to its existing debt facility with CRG Servicing LLC.

• EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020

  10/7/2020

  Q3 2020 net product revenues are estimated to be between $5.5- $5.9million, ashealthcare facilities began reopening from COVID-19 closures

• EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

  9/10/2020

  EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, will present in two upcoming virtual conferences in September. Cantor Virtual Healthcare Conference Date: Tuesday, September 15 Time: 4:40 PM Eastern Time H.C. Wainwright 22nd Annual Global Investment Conference Date

• EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

  8/24/2020

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® 9%.

• EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements

  8/20/2020

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China-based ophthalmic pharmaceutical platform company, announced the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets.

• EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments

  8/5/2020

  Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic

• EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®

  8/4/2020

  Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers

• EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information

  7/29/2020

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020.

• EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting

  7/27/2020

  EyePoint Pharmaceuticals, Inc. announced the presentation of data supporting YUTIQ® 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye.

• EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer

  7/13/2020

  World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline

• EyePoint Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:30 AM ET.